VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'

Market by 2FIRSTS.ai
Dec.13.2024
VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL introduces new open system e-cigarette, Ace Max, featuring world's largest HD touch screen, now available in UK.

Special announcement:

This article is intended for internal industry communication only and does not make any recommendations for brands or products.

The images presented in this article are used solely to depict factual information and are not intended as advertisements for any products.

This article prohibits access for minors.


Recently, it has come to the attention of 2Firsts that the well-known e-cigarette brand VOZOL has launched a new open system, the VOZOL Ace Max, on its official website. The brand's promotion claims that this product features "the world's largest high-definition touch screen." Currently, the VOZOL Ace Max is available on the websites of e-cigarette distributors in the UK, such as vapesuperstore and ideavape.

 

VOZOL official website showcases its first open system product

 

VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL Ace Max | Image Source: VOZOL Official Website

 

Specifically, the product features of VOZOL Ace Max are as follows:

 

VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL Ace Max product specifications | Graphic: 2Firsts

 

According to the information posted on the official website of the VOZOL brand, VOZOL Ace Max is the only open system product showcased by the brand. It belongs to the "ACE" product series and its main feature is the 1.47-inch touch screen display, which shows data including power, inhalation count, and battery level.

 

The only e-liquid product displayed on the VOZOL official website

 

On the official website for VOZOL Ace Max, the "Product Recommendations" section displays an e-liquid product available in two nicotine concentrations, 20mg and 50mg, and two sizes, 10ml and 30ml. The brand also offers a variety of 60 different flavors for consumers to choose from.

 

VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL E-liquid | Image source: VOZOL official website

 

This e-liquid is currently the only e-liquid product displayed on the official website of the VOZOL brand.

 

It is reported that VOZOL Ace Max was officially launched on the official website of VOZOL in November this year. Currently, the product is available on e-cigarette distributor websites such as vapesuperstore and ideavape in the UK, with a selling price of around £29.99.

 

VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL Ace Max real picture | Image source: ideavape

 

2Firsts discovered through online e-cigarette retailers such as vapesourcing, vapeclub, zerovapes, that the VOZOL brand mainly sells disposable e-cigarettes and a few pod systems. As of the time of writing, there have been no other open system products from the VOZOL brand except for the VOZOL Ace Max.

 

2Firsts will continue to monitor the performance and market trends of e-cigarette products globally, providing the public with accurate and authoritative industry information.

 


The product section focuses on providing readers with the latest information in the tobacco industry, welcoming submissions from readers to share the newest products in the e-cigarette field.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa plans to publish its first vapor products directory on November 16, 2026, after which products not listed will be prohibited from sale or offer for sale in the state. The Department of Revenue expects to begin penalty enforcement on December 17, following an initial 21-business-day period focused on compliance education. Under House File 2677, retailers, distributors and wholesalers selling unlisted products face civil penalties of $300 per product per day, while manufacturers face $1,000 per product per day. Eligibility extends to FDA-authorized products and certain products meeting historical marketing and pending PMTA requirements. The directory program resumed after a federal appeals court vacated a preliminary injunction in July 2026.
Regulations
Nov.05
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22